Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New diabetes pill shows promise in early safety trial

NCT ID NCT04426474

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested an oral drug called LY3502970 in 68 adults with type 2 diabetes. The main goal was to check safety and side effects, while also measuring how the drug moves through the body and affects blood sugar. Participants took the drug or a placebo for up to 18 weeks, with frequent visits and blood tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LY3502970 (oral drug)
What this could lead to
If successful, this could lead to a new oral medication to help control blood sugar in people with type 2 diabetes.
What could go wrong
This is an early Phase 1 trial focused on safety, not effectiveness. The drug may cause side effects or fail to improve blood sugar in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

68 people

The number who actually took part.

Started

Oct 2020

Finished

Jul 2021

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have type 2 diabetes mellitus (T2DM) for at least 6 months * Have a glycated hemoglobin (HbA1c) value at screening of greater than or equal to (≥)7.0 percent (%) and less than or equal to (≤)10.5% and are treated with diet and exercise alone or a stable dose of metformin for at least 3 months prior to screening * Have a body weight of ≥45 kilograms (kg) and have a body mass index of 18.5 to 45 kilograms per square meter (kg/m²), inclusive * Have had a stable body weight for the 3 months prior to screening (less than \[\<\]5% body weight change) * Males and females (not considered woman of childbearing potential) Exclusion Criteria: * Have type 1 diabetes mellitus, latent autoimmune diabetes in adults or have had an episode of ketoacidosis or hyperosmolar state requiring hospitalization in the 6 months prior to screening * Have had any of the following within the past 6 months prior to screening: myocardial infarction, unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), transient ischemic attack, cerebrovascular accident or decompensated congestive heart failure, or currently have New York Health Association Class III or IV heart failure * Show evidence of hepatitis B, and/or positive hepatitis B surface antigen * Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies * Any glucose-lowering medications other than metformin within 3 months prior to screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2

Contacts and locations

Locations

  • Clinical Pharmacology of Miami

    Hialeah, Florida, 33014, United States

  • Endeavor Clinical Trials

    San Antonio, Texas, 78229, United States

  • Hassman Research Institute

    Marlton, New Jersey, 08053, United States

  • Midwest Clinical Research Unit

    Dayton, Ohio, 45417, United States

  • Profil Institut für Stoffwechselforschung

    Neuss, North Rhine-Westphalia, 41460, Germany

  • Profil Mainz

    Mainz, 55116, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.